Dashboard
Manage Tickers

ITRMIterum Therapeutics plc


$ 1.10 $ -0.01 (-0.91 %)    

Wednesday, 18-Sep-2024 15:59:59 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 472.49 $ -2.05 (-0.43 %)
DIA $ 416.26 $ -1.07 (-0.26 %)
SPY $ 562.20 $ -1.67 (-0.3 %)
TLT $ 99.62 $ -1.25 (-1.24 %)
GLD $ 235.53 $ -1.83 (-0.77 %)
$ na
$ 1.09 x 690
$ 1.10 x 299
-- - --
$ 0.62 - $ 2.50
172,368
na
24.75M
$ 1.41
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

trading-halt-halt-status-updated-at-72500-am-et-quotation-resumption-news-and-resumption-times
Trading Halt: Halt status updated at 7:25:...
09/10/2024 11:25:03

iterum-therapeutics-reports-fda-advisory-committee-discussion-of-oral-sulopenem-fda-decision-expected-by-pdufa-goal-date-of-october-25-2024
Iterum Therapeutics Reports FDA Advisory C...
09/10/2024 11:06:00

Iterum announced that a meeting of the FDA Antimicrobial Drugs Advisory Committee (AMDAC) took place on September 9, 2024 at wh...

hc-wainwright--co-reiterates-buy-on-iterum-therapeutics-maintains-5-price-target
HC Wainwright & Co. Reiterates Buy on Iter...
09/10/2024 10:56:58

HC Wainwright & Co. analyst Ed Arce reiterates Iterum Therapeutics (NASDAQ:ITRM) with a Buy and maintains $5 price target.

trading-halt-halted-at-65500-am-et---trading-halt-halt-news-pending
Trading Halt: Halted at 6:55:00 a.m. ET - ...
09/09/2024 10:55:03

hc-wainwright--co-maintains-buy-on-iterum-therapeutics-lowers-price-target-to-5
HC Wainwright & Co. Maintains Buy on Iteru...
08/15/2024 11:10:47

HC Wainwright & Co. analyst Ed Arce maintains Iterum Therapeutics (NASDAQ:ITRM) with a Buy and lowers the price target f...

iterum-therapeutics-q2-2024-adj-eps-023-beats-045-estimate-cash-cash-equivalents-and-short-term-investments-were-117m-will-be-sufficient-to-fund-its-operations-into-2025
Iterum Therapeutics Q2 2024 Adj. EPS $(0.2...
08/14/2024 11:07:05

iterum-therapeutics-announces-expiration-and-results-of-rights-offering-estimates-that-it-will-receive-aggregate-gross-proceeds-of-74m-not-including-estimated-expenses-relating-to-the-rights-offering-and-payable-by-the-company-of-11m
Iterum Therapeutics Announces Expiration A...
08/06/2024 21:35:28

Iterum Therapeutics plc (NASDAQ:ITRM) (the "Company"), a clinical-stage pharmaceutical company focused on developing ne...

iterum-therapeutics-announces-uspto-notice-of-allowance-for-two-us-patents-and-issuance-of-canadian-patent-by-cipo-for-sulopenem-etzadroxil-and-probenecid-oral-sulopenem
Iterum Therapeutics Announces USPTO Notice...
08/02/2024 12:04:11

iterum-therapeutics-commences-121-per-unit-rights-offering-for-antibiotics-development
Iterum Therapeutics Commences $1.21 Per Un...
07/22/2024 11:43:09

Iterum Therapeutics plc (NASDAQ:ITRM) (the "Company"), a clinical-stage pharmaceutical company focused on developing ne...

hc-wainwright--co-reiterates-buy-on-iterum-therapeutics-maintains-6-price-target
HC Wainwright & Co. Reiterates Buy on Iter...
06/21/2024 17:40:20

HC Wainwright & Co. analyst Ed Arce reiterates Iterum Therapeutics (NASDAQ:ITRM) with a Buy and maintains $6 price target.

iterum-therapeutics-announces-fda-to-review-new-drug-application-for-oral-sulopenem-etzadroxilprobenecid-for-uncomplicated-utis-in-advisory-committee-meeting-on-september-9-2024-discussion-to-focus-on-antimicrobial-stewardship-and-target-patient-population
Iterum Therapeutics Announces FDA To Revie...
06/21/2024 12:02:20

hc-wainwright--co-reiterates-buy-on-iterum-therapeutics-maintains-6-price-target
HC Wainwright & Co. Reiterates Buy on Iter...
05/31/2024 16:40:39

HC Wainwright & Co. analyst Ed Arce reiterates Iterum Therapeutics (NASDAQ:ITRM) with a Buy and maintains $6 price target.

iterum-therapeutics-announced-that-the-us-fda-has-acknowledged-receipt-of-the-resubmission-of-the-nda-for-sulopenem-etzadroxilprobenecid-for-the-treatment-of-utis
Iterum Therapeutics Announced That The U.S...
05/31/2024 12:03:15

hc-wainwright--co-reiterates-buy-on-iterum-therapeutics-maintains-6-price-target
HC Wainwright & Co. Reiterates Buy on Iter...
05/14/2024 10:41:55

HC Wainwright & Co. analyst Ed Arce reiterates Iterum Therapeutics (NASDAQ:ITRM) with a Buy and maintains $6 price target.

iterum-therapeutics-cash-cash-equivalents-and-short-term-investments-were-182-million-at-march-31-2024-will-be-sufficient-to-fund-its-operations-into-2025
Iterum Therapeutics' Cash, Cash Equivalent...
05/13/2024 11:03:43

iterum-therapeutics-q1-2024-adj-eps-058-beats-072-estimate
Iterum Therapeutics Q1 2024 Adj EPS $(0.58...
05/13/2024 11:02:41

hc-wainwright--co-reiterates-buy-on-iterum-therapeutics-maintains-6-price-target
HC Wainwright & Co. Reiterates Buy on Iter...
04/30/2024 10:37:41

HC Wainwright & Co. analyst Ed Arce reiterates Iterum Therapeutics (NASDAQ:ITRM) with a Buy and maintains $6 price target.

iterum-therapeutics-resubmits-new-drug-application-to-fda-for-oral-sulopenem
Iterum Therapeutics Resubmits New Drug App...
04/29/2024 12:03:18

on-april-3-iterum-therapeutics-received-letter-from-nasdaq-indicating-that-it-is-not-in-compliance-with-nasdaq-listing-rule
On April 3, Iterum Therapeutics Received L...
04/05/2024 20:36:30

- SEC Filing

hc-wainwright--co-reiterates-buy-on-iterum-therapeutics-maintains-6-price-target
HC Wainwright & Co. Reiterates Buy on Iter...
04/01/2024 10:23:51

HC Wainwright & Co. analyst Ed Arce reiterates Iterum Therapeutics (NASDAQ:ITRM) with a Buy and maintains $6 price target.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION